Free Access
This article is a note for: [this article]

Table I.

Therapeutic monoclonal antibodies in oncology.

Name (trade name) Species/Format (isotype) Approval date* Target Indication°
Edrecolomab (Panorex) Mouse (IgG2a, κ) 1995¥ (Ger.)°° EpCAM CRC**
Rituximab (Mabthera)+ Chimeric (IgG1, κ) 1997 CD20 NHL**
Trastuzumab (Herceptin) Humanized (IgG1, κ) 1998 HER2/neu Breast Cancer
Gemtuzumab (Mylotarg) Humanized (IgG4, κ)# 2000¥ CD33 AML**
Alemtuzumab (MabCampath) Humanized (IgG1, κ) 2001 CD52 CLL**
Ibritumomab tiuxetan (Zevalin) Mouse (IgG1, κ) (conjugated to Ind111/Y99) 2002 CD20 NHL**
Tositumomab-I131 (Bexxar) Mouse (IgG2a, κ) (conjugated to I131) 2003 CD20 NHL**
I131-Vivatuxin/I131-chTNT Chimeric IgG 2003 (PRC)°° NT Ag*** Lung Cancer
Cetuximab (Erbitux) Chimeric (IgG1, κ) 2004 EGF-R Head & Neck Cancer
Bevacizumab (Avastin) Humanized (IgG1, κ) 2004 VEGF-A CRC**
Metuximab (I131-Licartin) Chimeric (Fab’)2 2005 (PRC) CD147 HCC**
Nimotuzumab (TheraCIM) (BIOMab EGFR) (CIMAHer) Humanized (IgG1, κ) 2005++ (Singapore) (India) (Cuba) EGF-R Head & Neck Cancer Nasopharyngeal cancer, Glioma
Panitimumab (Vectibix) Human (IgG2, κ) 2006 EGF-R CRC
Catumaxomab (Removab) Mouse IgG2a/rat IgG2b°°° 2009 EpCAM/CD3 Malignant Ascites
Ofatumumab (Arzerra) Human (IgG1, κ) 2009 CD20 CLL
Denosumab (Prolia) Human (IgG2, κ) 2010 RANK-L Bone Metastases
Ipilimumab (Yervoy) Human (IgG1, κ) 2011 CTLA-4 Melanoma
Brentuximab vedotin (Adcentris) Chimeric (IgG1, κ)## 2011 CD30 Hodgkin Lymphoma, ALCL**
Pertuzumab (Perjeta) Humaniszed (IgG1, κ) 2012 HER2/neu Breast Cancer

First year registration (EMA, FDA or SFDA). EMA: European Medicines Agency (ex-EMEA) (EU); FDA: Food and Drug Administration (USA); SFDA: State Food and Drug Administration (RPC).


Only the first indication is indicated (except denosumab whose first indication was post-menopausal osteoporosis).


Rituxan™ in the USA.


ALCL: anaplastic large-cell lymphoma; CRC: colorectal cancer; HCC: hepatocellular carcinoma; AML: acute myeloid leukemia; CLL: chronic lymphocytic leukemia; NHL: non-Hodgkin lymphoma.


Immunoconjugated to ozogamycin.


Discontinued (edrecolomab: withdrawn from market after two phase III trials showing no patient benefit; gemtuzumab withdrawn from market in 2010 due to unfavourable risk/benefit ratio).


Ger.: Federal Republic of Germany; PRC: People’s Republic of China.


NT Ag: necrotic tumor antigen (TNT: tumor necrotic therapy).


Orphan drug status granted by FDA and EMA for glioma treatment and by EMA for pancreatic cancer treatment.


Quadroma: bispecific antibody obtained by fusion of two hybridomas.


Immunoconjugated to monomethyl auristatin E (MMAE).

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.